Comparative safety of the sodium glucose co-transporter 2 (SGLT2) inhibitors: a systematic review and meta-analysis
Objective To estimate the association between the use of sodium glucose co-transporter-2 (SGLT2) inhibitors and postmarket harms as identified by drug regulatory agencies.Design We conducted a systematic review and meta-analysis of randomised controlled trials (RCT). Six large databases were searche...
Saved in:
Main Authors: | Kris Aubrey-Bassler, John-Michael Gamble, Jennifer R Donnan, Catherine A Grandy, Eugene Chibrikov, Carlo A Marra, Karissa Johnston, Michelle Swab, Jenna Hache, Daniel Curnew, Hai Nguyen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2019-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/9/1/e022577.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advances in sodium-glucose transporter protein 2 inhibitors and tumors
by: Jiaqi Wang, et al.
Published: (2025-02-01) -
The SGLT-2 Inhibitors and their Role in the Treatment of Heart Failure - A Review of Literature
by: Silvia Ciraolo, et al.
Published: (2025-02-01) -
Impact of Hospitalization on Continuation of SGLT2 Inhibitors and GLP-1 Receptor Agonists for Comorbidities in Patients with Type 2 Diabetes
by: Bethany Murphy, et al.
Published: (2025-01-01) -
The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus
by: Rujie Zheng, et al.
Published: (2025-02-01) -
Mitochondrial insights on antidiabetic therapies: Differential impacts of SGLT2i, GLP-1, and insulin
by: Yu-Hsiang Lin, et al.
Published: (2025-02-01)